Recent Trends in Medication Usage for the Treatment of Juvenile Idiopathic Arthritis and the Influence of Tumor Necrosis Factor Inhibitors

REFERENCES

1. 1.↵
   1. Ravelli A,
   2. Martini A

   . Juvenile idiopathic arthritis. Lancet 2007;369:767–78.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Giannini EH,
   2. Brewer EJ,
   3. Kuzmina N,
   4. Shaikov A,
   5. Maximov A,
   6. Vorontsov I,
   7. et al.

   Methotrexate in resistant juvenile rheumatoid arthritis. Results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and The Cooperative Children’s Study Group. N Engl J Med 1992;326:1043–9.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Lovell DJ,
   2. Giannini EH,
   3. Reiff A,
   4. Cawkwell GD,
   5. Silverman ED,
   6. Nocton JJ,
   7. et al.

   Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group. N Engl J Med 2000;342:763–9.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Lovell DJ,
   2. Ruperto N,
   3. Goodman S,
   4. Reiff A,
   5. Jung L,
   6. Jarosova K,
   7. et al.

   Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008;359:810–20.

   OpenUrlCrossRefPubMed
5. 5.↵
   1. Ruperto N,
   2. Lovell DJ,
   3. Cuttica R,
   4. Woo P,
   5. Meiorin S,
   6. Wouters C,
   7. et al.

   Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension. Ann Rheum Dis 2010;69:718–22.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Ruperto N,
   2. Lovell DJ,
   3. Quartier P,
   4. Paz E,
   5. Rubio-Pérez N,
   6. Silva CA,
   7. et al.

   Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial. Lancet 2008;372:383–91.

   OpenUrlCrossRefPubMed
7. 7.↵
   1. De Benedetti F,
   2. Brunner HI,
   3. Ruperto N,
   4. Kenwright A,
   5. Wright S,
   6. Calvo I,
   7. et al.

   Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2385–95.

   OpenUrlCrossRefPubMed
8. 8.↵
   1. Ruperto N,
   2. Brunner HI,
   3. Quartier P,
   4. Constantin T,
   5. Wulffraat N,
   6. Horneff G,
   7. et al.

   Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med 2012;367:2396–406.

   OpenUrlCrossRefPubMed
9. 9.↵
   1. Quartier P,
   2. Allantaz F,
   3. Cimaz R,
   4. Pillet P,
   5. Messiaen C,
   6. Bardin C,
   7. et al.

   A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial). Ann Rheum Dis 201;70:747–54.
10. 10.↵
    1. Foeldvari I,
    2. Szer IS,
    3. Zemel LS,
    4. Lovell DJ,
    5. Giannini EH,
    6. Robbins JL,
    7. et al.

    A prospective study comparing celecoxib with naproxen in children with juvenile rheumatoid arthritis. J Rheumatol 2009;36:174–82.

    OpenUrlAbstract/FREE Full Text
11. 11.↵
    1. Lovell DJ,
    2. Reiff A,
    3. Ilowite NT,
    4. Wallace CA,
    5. Chon Y,
    6. Lin SL,
    7. et al.

    Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008;58:1496–504.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Prince FH,
    2. Twilt M,
    3. ten Cate R,
    4. van Rossum MA,
    5. Armbrust W,
    6. Hoppenreijs EP,
    7. et al.

    Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann Rheum Dis 2009;68:635–41.

    OpenUrlAbstract/FREE Full Text
13. 13.↵
    1. Beukelman T,
    2. Patkar NM,
    3. Saag KG,
    4. Tolleson-Rinehart S,
    5. Cron RQ,
    6. DeWitt EM,
    7. et al.

    2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res 2011;63:465–82.

    OpenUrlCrossRef
14. 14.↵
    1. Beukelman T,
    2. Ringold S,
    3. Davis TE,
    4. DeWitt EM,
    5. Pelajo CF,
    6. Weiss PF,
    7. et al.

    Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry. J Rheumatol 2012;39:1867–74.

    OpenUrlAbstract/FREE Full Text
15. 15.↵
    1. Upchurch KS,
    2. Kay J

    . Evolution of treatment for rheumatoid arthritis. Rheumatology 2012;51 Suppl 6:vi28–36.

    OpenUrlAbstract/FREE Full Text
16. 16.↵
    1. Horneff G,
    2. De Bock F,
    3. Foeldvari I,
    4. Girschick HJ,
    5. Michels H,
    6. Moebius D,
    7. et al.

    Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann Rheum Dis 2009;68:519–25.

    OpenUrlAbstract/FREE Full Text
17. 17.↵
    1. Schneeweiss S,
    2. Avorn J

    . A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005;58:323–37.

    OpenUrlCrossRefPubMed
18. 18.↵
    1. Sherry DD,
    2. Wallace CA,
    3. Kahn SJ

    . Pediatric rheumatology in adult rheumatology practices in Washington state. Arthritis Rheum 1996;39:1218–21.

    OpenUrlCrossRefPubMed
19. 19.↵
    1. Mayer ML,
    2. Sandborg CI,
    3. Mellins ED

    . Role of pediatric and internist rheumatologists in treating children with rheumatic diseases. Pediatrics 2004;113:e173–81.

    OpenUrlAbstract/FREE Full Text
20. 20.↵
    1. American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiinflammatory Drugs

    . Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum 2008;59:1058–73.

    OpenUrlCrossRefPubMed
21. 21.↵
    1. McDonough AK,
    2. Curtis JR,
    3. Saag KG

    . The epidemiology of glucocorticoid-associated adverse events. Curr Opin Rheumatol 200;20:131–7.
22. 22.↵
    1. Shenoi S,
    2. Wallace CA

    . Tumor necrosis factor inhibitors in the management of juvenile idiopathic arthritis: an evidence-based review. Paediatr Drugs 2010;12:367–77.

    OpenUrlCrossRefPubMed
23. 23.↵
    1. Del Rincón I,
    2. Battafarano DF,
    3. Restrepo JF,
    4. Erikson JM,
    5. Escalante A

    . Glucocorticoid dose thresholds associated with all-cause and cardiovascular mortality in rheumatoid arthritis. Arthritis Rheumatol 2014;66:264–72.

    OpenUrlCrossRefPubMed
24. 24.↵
    1. Nam JL,
    2. Winthrop KL,
    3. van Vollenhoven RF,
    4. Pavelka K,
    5. Valesini G,
    6. Hensor EM,
    7. et al.

    Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010;69:976–86.

    OpenUrlAbstract/FREE Full Text
25. 25.↵
    1. Bulatović M,
    2. Heijstek MW,
    3. Verkaaik M,
    4. van Dijkhuizen EH,
    5. Armbrust W,
    6. Hoppenreijs EP,
    7. et al.

    High prevalence of methotrexate intolerance in juvenile idiopathic arthritis: development and validation of a methotrexate intolerance severity score. Arthritis Rheum 2011;63:2007–13.

    OpenUrlCrossRefPubMed